[SCHEDULE 13D/A] UNIVERSAL INSURANCE HLDG, INC. SEC Filing

Rhea-AI Filing Summary

Renalytix plc (RNLX) filed Post-Effective Amendment No. 1 to its Form S-8 (Reg. No. 333-274732). The amendment terminates the effectiveness of the original registration statement and dere­gisters all ordinary shares (£0.0025 par value) that remain unissued under two employee programs: (1) the 2020 Employee Share Purchase Plan and (2) the 2020 Equity Incentive Plan. No new securities will be offered pursuant to these plans under this registration after the filing becomes effective, which occurs automatically upon submission under Rule 464.

The company confirms its status as a non-accelerated filer, smaller reporting company, and emerging growth company. The document is signed by CEO James McCullough in London on 25 July 2025, with no additional signatures required under Rule 478.

Positive

• Deregisters unissued shares, eliminating a source of potential future shareholder dilution.

Negative

• Reduces share-based compensation flexibility by cancelling registration of plan shares.

Insights

Financial Analyst

TL;DR – Housekeeping amendment that removes unused equity from registration; negligible operational impact.

This S-8 POS simply withdraws unissued shares tied to Renalytix’s 2020 ESPP and Equity Incentive Plan. The move halts the ability to issue those particular shares, modestly reducing potential future dilution but also limiting equity-based compensation capacity. There are no financial metrics, capital raises, or strategic signals in the filing; therefore, the market impact is expected to be neutral and purely administrative.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 5)

UNIVERSAL INSURANCE HOLDINGS, INC

(Name of Issuer)

Common Stock, par value $0.01 per share

(Title of Class of Securities)

91359V107

(CUSIP Number)

Sean P. Downes
1110 W. Commercial Blvd., Suite 100
Fort Lauderdale, FL, 33309
(954) 958-1200

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

07/23/2025

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

SCHEDULE 13D

CUSIP No. 91359V107

1

Name of reporting person

Sean P. Downes

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

OO

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 1,568,710.00
8	Shared Voting Power 20,000.00
9	Sole Dispositive Power 1,568,710.00
10	Shared Dispositive Power 20,000.00

11

Aggregate amount beneficially owned by each reporting person

1,588,710.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

5.6 %

14

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13D

Item 1.	Security and Issuer
(a)	Title of Class of Securities: Common Stock, par value $0.01 per share
(b)	Name of Issuer: UNIVERSAL INSURANCE HOLDINGS, INC
(c)	Address of Issuer's Principal Executive Offices: 1110 W. Commercial Blvd., Suite 100, Fort Lauderdale, FLORIDA , 33309.
Item 2.	Identity and Background
(a)	Sean P. Downes
(b)	c/o Universal Insurance Holdings, Inc., 1110 West Commercial Blvd., Suite 100, Fort Lauderdale, Florida 33309
(c)	Executive Chairman
(d)	No
(e)	No
(f)	United States of America
Item 3.	Source and Amount of Funds or Other Consideration
	Mr. Downes acquired shares of Common Stock reported herein in connection with Mr. Downes' employment with the Company, including pursuant to an Executive Chairman Agreement and related Non-qualified Stock Option Agreements, Restricted Stock Unit Agreements and Performance Shares Agreements, each of which is incorporated herein by reference to Exhibits 1 through 11 of this Amendment No. 5 to Schedule 13D. Mr. Downes' also acquired certain shares of Common Stock reported herein via open market purchases.
Item 4.	Purpose of Transaction
	The response to Item 3 is incorporated by reference herein. Mr. Downes does not presently have any plan(s) or proposal(s) which relates to or would result in any of the following: the acquisition or disposition by any person of additional securities of the issuer; an extraordinary corporate transaction involving the issuer or its subsidiaries; a sale or transfer of a material amount of the issuer's or its subsidiaries' assets; any change in the present board of directors or management of the issuer; any material change in the present capitalization or dividend policy of the issuer; any other material change in the issuer's corporate structure; any changes to the issuer's charter, bylaws or instruments corresponding thereto which may impede the acquisition of control by any person; causing a class of securities of the issuer to be delisted from a national securities exchange or cease to be authorized to be quoted in an inter-dealer quotation system of a registered national securities association; or a class of equity securities of the issuer becoming eligible for termination of registration pursuant to Section 12(g)(4) of the Securities Exchange Act of 1934.
Item 5.	Interest in Securities of the Issuer
(a)	Mr. Downes may be deemed to beneficially own an aggregate of 1,588,710 shares of Common Stock, which amount includes options to purchase an aggregate of 534,325 shares of Common Stock exercisable within 60 days. This amount represents 5.6% of the outstanding shares of Common Stock of the Company. The percentage is based on 28,068,794 shares of Common Stock outstanding on July 23, 2025.
(b)	Mr. Downes has the sole power to vote and to dispose of 1,568,710 shares of Common Stock reported herein. Mr. Downes has shared power to vote and to dispose of 20,000 shares of Common Stock reported herein.
(c)	On June 12, 2025, Mr. Downes sold 25,000 shares of Common Stock at an average price of $26.9112. The shares were sold in multiple transactions at prices ranging from $26.74 to $27.035, inclusive. The sale was effected for Mr. Downes' account by a broker in the open market. On June 13, 2025, Mr. Downes sold 25,000 shares of Common Stock at an average price of $26.475. The shares were sold in multiple transactions at prices ranging from $26.35 to $26.75, inclusive. The sale was effected for Mr. Downes's account by a broker in the open market. On July 23, 2025, Mr. Downes received 687,960 shares of Common Stock in connection with the exercise of vested stock options. Of these shares, 546,115 were withheld to pay the exercise prices and satisfy tax withholding obligations.
(d)	This Item 5(d) is not applicable.
(e)	This Item 5(e) is not applicable.
Item 6.	Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer
	The response to Item 3 is incorporated by reference herein.
Item 7.	Material to be Filed as Exhibits.
	1. Executive Chairman Agreement, dated April 24, 2020 between Sean P. Downes and the Company (incorporated by reference to the Company's Current Report on Form 8-K, filed with the SEC on April 24, 2020). 2. Universal Insurance Holdings, Inc. 2021 Omnibus Incentive Plan (incorporated by reference to the Company's Registration Statement on Form S-8 filed on July 14, 2021). 3. Form of Restricted Stock Unit Agreement (incorporated by reference to the Company's Annual Report on Form 10-K, filed with the SEC on March 2, 2020). 4. Form of Notice of Grant of Restricted Stock Units Pursuant to the 2021 Omnibus Incentive Plan (incorporated by reference to the Company's Quarterly Report on Form 10-Q, filed with SEC on May 2, 2023). 5. Form of Notice of Grant on Non-Qualified Stock Option and Terms and Conditions of Non-Qualified Stock Option under the 2021 Omnibus Incentive Plan (incorporated by reference to the Company's Quarterly Report on Form 10-Q, filed with the SEC on May 2, 2022). 6. Form of Notice of Grant of Restricted Stock and Terms and Conditions of Restricted Stock Award under the 2021 Omnibus Incentive Plan (incorporated by reference to the Company's Quarterly Report on Form 10-Q, filed with the SEC on July 31, 2023). 7. Form of Notice of Grant on Performance Share Units and Terms and Conditions of Performance Share Units under the 2021 Omnibus Incentive Plan (incorporated by reference to the Company's Quarterly Report on Form 10-Q filed on July 29, 2022). 8. Form of Restricted Stock Unit Agreement (incorporated by reference to the Company's Annual Report on Form 10-K, filed with the SEC on February 28, 2024). 9. Form of Notice of Grant of Restricted Stock and Terms and Conditions of Restricted Stock Award under the 2021 Omnibus Incentive Plan (incorporated by reference to the Company's Quarterly Report on Form 10-Q, filed with the SEC on July 30, 2024). 10. Form of Universal Insurance Holdings, Inc. Performance Shares Agreement under the 2021 Omnibus Incentive Plan for grants in 2024 (incorporated by reference to the Company's Quarterly Report on Form 10-Q, filed with the SEC on October 30, 2024). 11. Form of Universal Insurance Holdings, Inc. Restricted Shares Agreement under the 2021 Omnibus Incentive Plan for grants in 2024 (incorporated by reference to the Company's Quarterly Report on Form 10-Q, filed with the SEC on October 30, 2024).

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Sean P. Downes

Signature:	/s/ Sean P. Downes
Name/Title:	Executive Chairman
Date:	07/25/2025

FAQ

What did Renalytix plc file on July 25 2025?

The company filed Post-Effective Amendment No. 1 to Form S-8 to deregister unissued shares under its 2020 ESPP and Equity Incentive Plan.

How many shares are being deregistered by RNLX?

The exact number is not specified; the amendment removes all remaining unissued ordinary shares registered under the two 2020 plans.

Will Renalytix still issue shares under the 2020 plans?

No. By terminating the registration statement, no additional shares can be issued under those plans via this filing.

Does this filing affect Renalytix’s filer status?

The company remains a non-accelerated filer, smaller reporting company, and emerging growth company, as indicated in the amendment.

Who signed the Post-Effective Amendment for Renalytix?

James McCullough, Chief Executive Officer and Director, signed the document in London.